• Evidences have suggested that impairment of CK

  2024-11-05

  

  Evidences have suggested that impairment of CK activity contributes to inhibition of Na+, K+-ATPase and H+-ATPase activities during infectious diseases, since these ATPases are dependent of ATP, as observed by Baldissera et al. [31] in fish experimentally infected by Aeromonas caviae. We observed th

• Ac-IETD-AFC Atherosclerosis is a chronic lipid

  2024-11-04

  

  Atherosclerosis is a chronic lipid metabolism disorder linked with lipid accumulation within the arterial wall and subsequent formation of foam cells and vascular disease [96], [97]. The level of apelin is decreased in human atherosclerotic coronary arteries [4], and coronary collateral formation in

• Several strategies have been employed to design and engineer

  2024-11-04

  

  Several strategies have been employed to design and engineer peptide biosensors of kinase activity, which are quite different from the strategies developed to generate genetically encoded KARs. In all cases, PHA-848125 induces changes in the spectral properties of the fluorophore(s) incorporated in

• At Johns Hopkins Aramco Health JHAH we started

  2024-11-04

  

  At Johns Hopkins Aramco Health (JHAH), we started an ASP in 2011 with an educational program of physicians and pharmacist. The program was enhanced mid-2012 with the following interventions: a re-designed antibiotic sensitivity report [2], intravenous to oral conversion program, vancomycin pharmacok

• In the present study a splice acceptor site mutation c

  2024-11-04

  

  In the present study, a splice acceptor site mutation (c.1769-1G > C) was identified in AR gene from patients with CAIS. The c.1769-1G > C mutation results in replacement of the normal sequence (CAG/G) with a new sequence (CAC/G) at the splice acceptor site of intron 2. In the splice acceptor site

• The preferential expression of ALOX B

  2024-11-04

  

  The preferential expression of ALOX15B in human macrophages may explain why human genetic studies investigating the association of ALOX15 with cardiovascular disease did not show consistent results. Two rare functional polymorphisms have been characterized in the ALOX15 gene, which leads to increase

• br Acknowledgments This work was

  2024-11-04

  

  Acknowledgments This work was supported by a grant of the Romanian National Authority for Scientific Research, CNCS – UEFISCDI, project no. PN-II-ID-PCE-2011-3-0571, awarded to F.A.M. D.V.N. was co-financed from the European Social Fund through Sectorial Operational Program Human Resources Develo

• About this report Alzheimer s

  2024-11-04

  

  About this report 2018 Alzheimer's Disease Facts and Figures is a statistical resource for U.S. data related to Alzheimer's disease, the most common cause of dementia. Background and context for interpreting the data are contained in the Overview. Additional sections address prevalence, mortality a

• br Conclusion br Conflict of interest br Acknowledgements br

  2024-11-04

  

  Conclusion Conflict of interest Acknowledgements Introduction Human salivary aldehyde dehydrogenase (hsALDH) (E.C. 1.2.1.5) is the first line of defence against toxic aldehydes in the oral cavity. HsALDH is primarily a dimeric, class 3 ALDH (ALDH3A1) specific for aromatic and long/medium

• br Acknowledgements Dr Paul J Gasser is supported by

  2024-11-04

  

  Acknowledgements Dr. Paul J. Gasser is supported by the National Institutes of Health (grant number R01DA032895), and the Charles E. Kubly Mental Health Research Center. Dr. Christopher A. Lowry is supported by the National Institutes of Health (grant number R21 MH116263), the Department of the N

• Systematic administration of ABT amino bromophenyl morpholin

  2024-11-04

  

  Systematic administration of ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl) pyrido[2,3-d] pyrimidine), a potent and selective non-nucleoside AK inhibitor, also generates analgesic effects in animal models of pain (Jarvis et al., 2000, Kowaluk et al., 2000, Suzuki et al., 2001), sug

• The assay performance was estimated using Z factors plotted

  2024-11-04

  

  The assay performance was estimated using Z′-factors (plotted in Fig. 2A) according to Zhang et al. calculated for each plate comparing positive (in the absence of an inhibitor) and negative controls (in the presence of an AdK inhibitor). The mean Z′-factor±SD was determined to be 0.7±0.1, indicativ

• br Conflict of interest br Financial support

  2024-11-04

  

  Conflict of interest Financial support Acknowledgments This work was supported by the Japanese Millennium project. We thank all members of the Center for Genomic Medicine of RIKEN and Dainippon-Sumitomo Pharma Co., Ltd. for supporting this study. We are also grateful to members of the Hiros

• Small kinase inhibitors have been developed to block AXL by

  2024-11-01

  

  Small kinase inhibitors have been developed to block AXL by interacting with the kinase cytoplasmic ATP binding site. Up to date, no AXL selective kinase inhibitors are marketed. As depicted in , some marketed kinase inhibitors such as Bosutinib and Cabozantinib or kinase inhibitors in clinical pha

• Our data indicate that the D domain only needs to

  2024-11-01

  

  Our data indicate that the D1 domain only needs to hydrolyze ATP a few times, or perhaps even just once, during the processing of a given substrate molecule, whereas the D2 domain hydrolyzes ATP many times. Consistent with this model, only D2 contains the canonical aromatic pore loop residues implic

7928 records 50/529 page Previous Next First page 上5页 4647484950 下5页 Last page